(3aS,6aR)-4-methoxy-3a,4,6,6a-tetrahydro-3H-furo[2,3-c]furan-2-one

We are (3aS,6aR)-4-methoxy-3a,4,6,6a-tetrahydro-3H-furo[2,3-c]furan-2-one CAS:501921-30-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (3aS,6aR)-4-methoxy-3a,4,6,6a-tetrahydro-3H-furo[2,3-c]furan-2-one
CAS.NO: 501921-30-8
Synonyms:
(3aS,6aR)-4-Methoxytetrahydrofuro[3,4-b]furan-2(3H)-one

Molecular Formula:C7H10O4
Molecular Weight:158.15200

Physical and Chemical Properties:
Density: 1.26g / cm3
Boiling point: 311.6ºC at 760 mmHg
Melting point: /
Flash point: 140.6±27.9 °C
Refractive index: 1.482

Specification:
Appearance:white crystalline powder
Purity:≥99%
Moisture Content: ≤0.1%
Impurity: ≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Darunavir CAS:206361-99-1
Intermediates ofDarunavir ethanolate CAS:635728-49-3

Related News: Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important.1198396-29-0 An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.trans,trans-2,4-Nonadienal An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.2-Isopropylthioxanthone CAS:5495-84-1 This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy.Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.